The industrial design, translation, and development strategies for long-acting peptide delivery

References

• Muttenthaler M, King GF, Adams DJ, et al. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309–325.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7(1):48–75.
   PubMed Web of Science ®Google Scholar
• Henninot A, Collins JC, Nuss JM. The current state of peptide drug discovery: back to the future? J Med Chem. 2018;61(4):1382–1414.
   PubMed Web of Science ®Google Scholar
• Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026, by Research and Markets. https://www.researchandmarkets.com/reports/4896465/global-peptide-therapeutics-market-and-clinical
   Google Scholar
• Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–2707.
   PubMed Web of Science ®Google Scholar
• Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015;17(1):134–143.
   PubMed Web of Science ®Google Scholar
• Ibeanu N, Egbu R, Onyekuru L, et al., Injectables and depots to prolong drug action of proteins and peptides. Pharmaceutics. 12(10): 999–1041. 2020.
   PubMed Web of Science ®Google Scholar
• Otvos L, Wade JD. Current challenges in peptide-based drug discovery. Front Chem. 2014;2:62.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A. Mechanisms influencing the pharmacokinetics and disposition of monoclonal antibodies and peptides. Drug Metab Dispos. 2019;47(10):1100–1110.
   PubMed Web of Science ®Google Scholar
• Shi Y, Lu A, Wang X, et al., A review of existing strategies for designing long-acting parenteral formulations: focus on underlying mechanisms, and future perspectives. Acta Pharm Sin B. 11(8): 2396–2415. 2021.
   PubMed Web of Science ®Google Scholar
• Nie T, Wang W, Liu X, et al. Sustained release systems for delivery of therapeutic peptide/protein. Biomacromolecules. 2021;22(6):2299–2324.
   PubMed Web of Science ®Google Scholar
• Pechenov S, Bhattacharjee H, Yin YD, et al. Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery. Adv Drug Deliv Rev. 2017;112:106–122.
   PubMed Web of Science ®Google Scholar
• Kowalczyk R, Harris PWR, Williams GM, et al. Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics. Adv Exp Med Biol. 2017;1030:185–227.
   PubMed Web of Science ®Google Scholar
• Van Witteloostuijn SB, Pedersen SL, Jensen KJ. Half-life extension of biopharmaceuticals using chemical methods: alternatives to pegylation. ChemMedChem. 2016;11(22):2474–2495.
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664–1669.
   PubMed Web of Science ®Google Scholar
• Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther. 2009;9(8):1035–1049.
   PubMed Web of Science ®Google Scholar
• Menacho-Melgar R, Decker JS, Hennigan JN, et al. A review of lipidation in the development of advanced protein and peptide therapeutics. J Control Release. 2019;295:1–12.
   PubMed Web of Science ®Google Scholar
• Schmid H. Peginesatide for the treatment of renal disease-induced anemia. Expert Opin Pharmacother. 2013;14(7):937–948.
   PubMed Web of Science ®Google Scholar
• Gorman DM, Lee LJ, Payne CD, et al. Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. Amino Acids. 2021;53(1):143–147.
   PubMed Web of Science ®Google Scholar
• Hubulashvili D, Marzella N. Romiplostim (Nplate), a treatment option for immune (idiopathic) thrombocytopenic purpura. Pharm Ther. 2009;34(9):482–485.
   Google Scholar
• Patch RJ, Zhang R, Edavettal S, et al. Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists. Eur J Med Chem. 2022;236:114330.
   PubMed Web of Science ®Google Scholar
• Simerska P, Moyle PM, Toth I. Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products. Med Res Rev. 2011;31(4):520–547.
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Flint A, Olsen AK, et al. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55(6):657–672.
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380.
   PubMed Web of Science ®Google Scholar
• Schultz HS, Østergaard S, Sidney J, et al. The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides. PLOS ONE. 2018;13(5):e0197407.
   PubMed Web of Science ®Google Scholar
• Madsen K, Knudsen LB, Agersoe H, et al. Structure−activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives:  importance of fatty acid length, polarity, and bulkiness. J Med Chem. 2007;50(24):6126–6132.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lomakin A, Kanai S, et al. The molecular basis for the prolonged blood circulation of lipidated incretin peptides: peptide oligomerization or binding to serum albumin? J Control Release. 2016;241:25–33.
   PubMed Web of Science ®Google Scholar
• Gallo M, Vanni D, Esposito S, et al. Oligomerization, albumin binding and catabolism of therapeutic peptides in the subcutaneous compartment: an investigation on lipidated GLP-1 analogs. J Pharm Biomed Anal. 2022;210:114566.
   PubMed Web of Science ®Google Scholar
• Tibble CA, Cavaiola TS, Henry RR. Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. Expert Rev Endocrinol Metab. 2013;8(3):247–259.
   PubMedGoogle Scholar
• Jeppesen PB. Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therap Adv Gastroenterol. 2012;5(3):159–171.
   PubMed Web of Science ®Google Scholar
• Hermanson T, Bennett CL, Macdougall IC. Peginesatide for the treatment of anemia due to chronic kidney disease – an unfulfilled promise. Expert Opin Drug Saf. 2016;15(10):1421–1426.
   PubMed Web of Science ®Google Scholar
• Lim YW, Tan WS, Ho KL, et al. Challenges and complications of poly(lactic-co-glycolic acid)-based long-acting drug product development. Pharmaceutics. 2022;14:3.
   Web of Science ®Google Scholar
• Wong SL, Lau DT-W, Baughman SA, et al. Pharmacokinetics and pharmacodynamics of a novel depot formulation of Abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. J Clin Pharmacol. 2004;44(5):495–502.
   PubMed Web of Science ®Google Scholar
• Doehn C, Sommerauer M, Jocham D. Degarelix for prostate cancer. Expert Opin Investig Drugs. 2009;18(6):851–860.
   PubMed Web of Science ®Google Scholar
• Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet. 2017;56(8):815–823.
   PubMed Web of Science ®Google Scholar
• Cuevas-Ramos D, Fleseriu M. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther. 2016;10:227–239.
   PubMed Web of Science ®Google Scholar
• Firmagon (Degarelix acetate): FDA-Approved Drugs. 2008. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022201s000_SumR.pdf.
   Google Scholar
• Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31–41.
   PubMed Web of Science ®Google Scholar
• Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55(5):497–504.
   PubMed Web of Science ®Google Scholar
• Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164(2):58–64.
   PubMedGoogle Scholar
• Frías JP. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2020;15(6):379–394.
   PubMed Web of Science ®Google Scholar
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.
   PubMed Web of Science ®Google Scholar
• Woodburn KW, Holmes CP, Wilson SD, et al. Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica. 2012;42(7):660–670.
   PubMed Web of Science ®Google Scholar
• Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001;22(5):405–417.
   PubMed Web of Science ®Google Scholar
• Adams MJ, Blundell TL, Dodson EJ, et al. Structure of rhombohedral 2 zinc insulin crystals. Nature. 1969;224(5218):491–495.
   Web of Science ®Google Scholar
• Hagedorn H, Jensen BN, and Krarup NB, et al. Protamine Insulinate. J Am Med Assoc. 1936;106(3):177–180.
   Google Scholar
• Krayenbuhl C, Rosenberg T. Crystalline protamine insulin. Reports of the Steno Memorial Hospital and the Nordisk Insulinlaboratorium. 1946;1:60–73.
   Google Scholar
• Pouget E, Fay N, Dujardin E, et al. Elucidation of the self-assembly pathway of lanreotide octapeptide into β-sheet nanotubes: role of two stable intermediates. J Am Chem Soc. 2010;132(12):4230–4241.
   PubMed Web of Science ®Google Scholar
• Valéry C, Pouget E, Pandit A, et al. Molecular origin of the self-assembly of lanreotide into nanotubes: a mutational approach. Biophys J. 2008;94(5):1782–1795.
   PubMed Web of Science ®Google Scholar
• Valéry C, Paternostre M, Robert B, et al. Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc Nat Acad Sci. 2003;100(18):10258–10262.
   PubMed Web of Science ®Google Scholar
• Valéry C, Artzner F, Robert B, et al. Self-association process of a peptide in solution: from β-sheet filaments to large embedded nanotubes. Biophys J. 2004;86(4):2484–2501.
   PubMed Web of Science ®Google Scholar
• Wolin EM, Manon A, Chassaing C, et al. Lanreotide depot: an antineoplastic treatment of carcinoid or neuroendocrine tumors. J Gastrointest Cancer. 2016;47(4):366–374.
   PubMedGoogle Scholar
• Carmichael JD, Carmichael J. Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits. Patient Prefer Adherence. 2012;6:73–82.
   PubMed Web of Science ®Google Scholar
• Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide AutogelR in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf). 2005;63(5):514–519.
   PubMed Web of Science ®Google Scholar
• Antonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol. 2004;56(4):471–476.
   PubMed Web of Science ®Google Scholar
• Kinna S, Ouberaï MM, Sonzini S, et al. Thermo-Responsive self-assembly of a dual glucagon-like peptide and glucagon receptor agonist. Int J Pharm. 2021;604:120719.
   PubMedGoogle Scholar
• Ouberai MM, Dos Santos ALG, Kinna S, et al. Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly. Nat Commun. 2017;8(1):1026.
   PubMedGoogle Scholar
• London NJS, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28(5):351–366.
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655–672.
   PubMed Web of Science ®Google Scholar
• Kwak HH, Shim WS, Choi MK, et al. Development of a sustained-release recombinant human growth hormone formulation. J Control Release. 2009;137(2):160–165.
   PubMed Web of Science ®Google Scholar
• Tomic I, Vidis-Millward A, Mueller-Zsigmondy M, et al. Setting accelerated dissolution test for PLGA microspheres containing peptide, investigation of critical parameters affecting drug release rate and mechanism. Int J Pharm. 2016;505(1–2):42–51.
   PubMedGoogle Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18.
   PubMed Web of Science ®Google Scholar
• Qi F, Wu J, Li H, et al. Recent research and development of PLGA/PLA microspheres/nanoparticles: a review in scientific and industrial aspects. Front Chem Sci Eng. 2019;13(1):14–27.
   Web of Science ®Google Scholar
• Schneider C, Langer R, Loveday D, et al. Applications of ethylene vinyl acetate copolymers (EVA) in drug delivery systems. J Control Release. 2017;262:284–295.
   PubMed Web of Science ®Google Scholar
• Lee SS, Hughes P, Ross AD, et al. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27(10):2043–2053.
   PubMed Web of Science ®Google Scholar
• Ruel-Gariépy E, Leroux J-C. In situ-forming hydrogels—review of temperature-sensitive systems. Eur J Pharm Biopharm. 2004;58(2):409–426.
   PubMed Web of Science ®Google Scholar
• Kanwar N, Sinha VR. In situ forming depot as sustained-release drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2019;36(2):93–136.
   PubMed Web of Science ®Google Scholar
• Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;1(12):1–17.
   Web of Science ®Google Scholar
• Wu Z, Alany RG, Tawfeek N, et al. A study of microemulsions as prolonged-release injectables through in-situ phase transition. J Control Release. 2014;174:188–194.
   PubMed Web of Science ®Google Scholar
• Zabara A, Mezzenga R. Controlling molecular transport and sustained drug release in lipid-based liquid crystalline mesophases. J Control Release. 2014;188:31–43.
   PubMed Web of Science ®Google Scholar
• Swaminathan J, Ehrhardt C. Liposomal delivery of proteins and peptides. Expert Opin Drug Deliv. 2012;9(12):1489–1503.
   PubMed Web of Science ®Google Scholar
• Agarwal P, Rupenthal ID. Injectable implants for the sustained release of protein and peptide drugs. Drug Discov Today. 2013;18(7–8):337–349.
   PubMed Web of Science ®Google Scholar
• Dunn RL, English JP, Cowsar DR. et al. Biodegradable in-situ forming implants and methods of producing the same. US Pat. 1994;5340849.
   Google Scholar
• ELIGARD®. Leuprolide acetate for injectable suspension, FDA-approved drugs, 2002. https://www.tolmar.com/products/eligard.
   Google Scholar
• Heller J, Barr J, Ng SY, et al. Poly(ortho esters): synthesis, characterization, properties and uses. Adv Drug Deliv Rev. 2002;54(7):1015–1039.
   PubMed Web of Science ®Google Scholar
• Nkanga CI, Fisch A, Rad-Malekshahi M, et al. Clinically established biodegradable long acting injectables: an industry perspective. Adv Drug Deliv Rev. 2020;167:19–46.
   PubMed Web of Science ®Google Scholar
• Tunn UW. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urol. 2011;11(1):15.
   PubMedGoogle Scholar
• Chu FM, Jayson M, Dineen MK, et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2002;168(3):1199–1203.
   PubMed Web of Science ®Google Scholar
• Thakur RRS, McMillan HL, Jones DS. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. J Control Release. 2014;176:8–23.
   PubMed Web of Science ®Google Scholar
• Van Tomme SR, Storm G, Hennink WE. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm. 2008;355(1–2):1–18.
   PubMedGoogle Scholar
• Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release. 2003;90(3):261–280.
   PubMed Web of Science ®Google Scholar
• Tamani F, Bassand C, Hamoudi MC, et al. Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: monolithic dispersions studied at lower temperatures. Int J Pharm. 2021;596:120220.
   PubMedGoogle Scholar
• Gasmi H, Siepmann F, Hamoudi MC, et al. Towards a better understanding of the different release phases from PLGA microparticles: dexamethasone-loaded systems. Int J Pharm. 2016;514(1):189–199.
   PubMedGoogle Scholar
• Fredenberg S, Wahlgren M, Reslow M, et al. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review. Int J Pharm. 2011;415(1–2):34–52.
   PubMed Web of Science ®Google Scholar
• Zhou J, Walker J, Ackermann R, et al. Effect of manufacturing variables and raw materials on the composition-equivalent PLGA microspheres for 1-month controlled release of leuprolide. Mol Pharm. 2020;17(5):1502–1515.
   PubMed Web of Science ®Google Scholar
• Wong CY, Al-Salami H, Dass CR. Microparticles, microcapsules and microspheres: a review of recent developments and prospects for oral delivery of insulin. Int J Pharm. 2018;537(1–2):223–244.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Hahn SK, Kim MJ, et al. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J Control Release. 2005;104(2):323–335.
   PubMed Web of Science ®Google Scholar
• Lupron depot (leuprolde acetate): FDA-approved drugs, 1989. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019732
   Google Scholar
• Davies PH, Stewart SE, Lancranjan I, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR ®) for the management of acromegaly. Clin Endocrinol (Oxf). 1998;48(3):311–316.
   PubMed Web of Science ®Google Scholar
• Fløgstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: long term treatment. J Clin Endocrinol Metab. 1997;82(1):23–28.
   PubMed Web of Science ®Google Scholar
• Grass P, Marbach P, Bruns C, et al. Sandostatin® LAR® (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism. 1996;45(Suppl 8):27–30.
   PubMed Web of Science ®Google Scholar
• Wysham C, Grimm M, Chen S. Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes Obesity Metab. 2013;15(10):871–881.
   PubMed Web of Science ®Google Scholar
• Painter NA, Morello CM, Singh RF, et al. An evidence-based and practical approach to using bydureon in patients with type 2 diabetes. J Am Board Fam Med. 2013;26(2):203–210.
   PubMed Web of Science ®Google Scholar
• Minze MG, Klein MS, Jernigan MJ, et al. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2013;33(6):627–638.
   PubMed Web of Science ®Google Scholar
• DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in Poly-(d,l -lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145–1154.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Okada H, Yamamoto Y, et al. In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers. Chem Pharm Bull. 1988;36(7):2576–2581.
   PubMed Web of Science ®Google Scholar
• Noguchi S, Kim HJ, Jesena A, et al. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer. Breast Cancer. 2016;23(5):771–779.
   PubMed Web of Science ®Google Scholar
• Fontana D, Mari M, Martinelli A, et al. 3-month formulation of goserelin acetate (‘Zoladex’ 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int. 2003;70(4):316–320.
   PubMed Web of Science ®Google Scholar
• Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 2012;64:72–82.
   Web of Science ®Google Scholar
• Tran VT, Benoît JP, Venier-Julienne MC. Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy? Int J Pharm. 2011;407(1–2):1–11.
   PubMed Web of Science ®Google Scholar
• Bak A, Leung D, Barrett SE, et al., Physicochemical and formulation developability assessment for therapeutic peptide delivery–a primer. AAPS J. 17(1): 144–155. 2015.
   PubMed Web of Science ®Google Scholar
• Payne RW, Manning MCJIPT, Peptide formulation: challenges and strategies. Innova Pharma Technol. 2009;28:64–68.
   Google Scholar
• Lantus (insulin glargine injection) solution for subcutaneous injection. FDA-Approved Drugs; 2000. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021081.
   Google Scholar
• Basaglar (insulin glargine injection): FDA-approved drugs, 2015. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
   Google Scholar
• Gao L, Liu G, Ma J, et al. Drug nanocrystals: in vivo performances. J Control Release. 2012;160(3):418–430.
   PubMed Web of Science ®Google Scholar
• Li X, Li L, Wang X, et al. Application of model‐based methods to characterize exenatide‐loaded double‐walled microspheres: in vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation. J Pharm Sci. 2012;101(10):3946–3961.
   PubMed Web of Science ®Google Scholar
• Giri TK, Choudhary C, Ajazuddin et al. Prospects of pharmaceuticals and biopharmaceuticals loaded microparticles prepared by double emulsion technique for controlled delivery. Saudi Pharm J. 2013;21(2):125–141.
   PubMed Web of Science ®Google Scholar
• Wan F, Yang M. Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying. Int J Pharm. 2016;498(1):82–95.
   PubMedGoogle Scholar
• Baldinger A, Clerdent L, Rantanen J, et al. Quality by design approach in the optimization of the spray-drying process. Pharm Dev Technol. 2012;17(4):389–397.
   PubMed Web of Science ®Google Scholar
• Cai Y, Wei L, Ma L, et al. Long-acting preparations of exenatide. Drug Des Devel Ther. 2013;7:963–970.
   PubMed Web of Science ®Google Scholar
• Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm. 2008;364(2):298–327.
   PubMed Web of Science ®Google Scholar
• Operti MC, Fecher D, van Dinther EAW, et al. A comparative assessment of continuous production techniques to generate sub-micron size PLGA particles. Int J Pharm. 2018;550(1):140–148.
   PubMedGoogle Scholar
• Zhang C, Yang L, Wan F, et al. Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery. Int J Pharm. 2020;585:119441.
   PubMed Web of Science ®Google Scholar
• Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27(1):26–34.
   PubMed Web of Science ®Google Scholar
• Breitenbach A, Li YX, Kissel T. Branched biodegradable polyesters for parenteral drug delivery systems. J Control Release. 2000;64(1):167–178.
   PubMed Web of Science ®Google Scholar
• Berkland C, King M, Cox A, et al. Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release. 2002;82(1):137–147.
   PubMed Web of Science ®Google Scholar
• Lee JS, Chae GS, Kim MS, et al. Degradation behaviour in vitro for poly(D,L-lactide-co-glycolide) as drug carrier. Biomed Mater Eng. 2004;14(2):185–192.
   PubMed Web of Science ®Google Scholar
• Xu Y, Kim CS, Saylor DM, et al. Polymer degradation and drug delivery in PLGA-based drug-polymer applications: a review of experiments and theories. J Biomed Mater Res B Appl Biomater. 2017;105(6):1692–1716.
   PubMed Web of Science ®Google Scholar
• Chen W, Palazzo A, Hennink WE, et al. Effect of particle size on drug loading and release kinetics of gefitinib-loaded PLGA microspheres. Mol Pharm. 2017;14(2):459–467.
   PubMedGoogle Scholar
• Fredenberg S, Wahlgren M, Reslow M, et al. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review. Int J Pharm. 2011;415(1):34–52.
   PubMedGoogle Scholar
• Andhariya JV, Jog R, Shen J, et al. In vitro-in vivo correlation of parenteral PLGA microspheres: effect of variable burst release. J Control Release. 2019;314:25–37.
   PubMed Web of Science ®Google Scholar
• Blanco-Prı́eto MaJ, Campanero MA, Besseghir K, et al. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres. J Control Release. 2004;96(3):437–448.
   PubMed Web of Science ®Google Scholar
• Chu D-F, Fu X-Q, Liu W-H, et al. Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm. 2006;325(1–2):116–123.
   PubMed Web of Science ®Google Scholar
• Vlugt Wensink KDF, de Vrueh R, Gresnigt MG, et al. Preclinical and clinical in vitro in vivo correlation of an hgh dextran microsphere formulation. Pharm Res. 2007;24(12):2239–2248.
   PubMed Web of Science ®Google Scholar
• Zolnik BS, Burgess DJ. Evaluation of in vivo–in vitro release of dexamethasone from PLGA microspheres. J Control Release. 2008;127(2):137–145.
   PubMed Web of Science ®Google Scholar
• Shen J, Choi S, Qu W, et al. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres. J Control Release. 2015;218:2–12.
   PubMed Web of Science ®Google Scholar
• Shen J, Lee K, Choi S, et al. A reproducible accelerated in vitro release testing method for PLGA microspheres. Int J Pharm. 2016;498(1–2):274–282.
   PubMed Web of Science ®Google Scholar
• Shen J, Burgess DJ. In vitro–in vivo correlation for complex non-oral drug products: where do we stand? J Control Release. 2015;219:644–651.
   PubMed Web of Science ®Google Scholar
• Andhariya JV, Shen J, Choi S, et al. Development of in vitro-in vivo correlation of parenteral naltrexone loaded polymeric microspheres. J Control Release. 2017;255:27–35.
   PubMed Web of Science ®Google Scholar
• Eliaz RE, Wallach D, Kost J. Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo. Pharm Res. 2000;17(12):1546–1550.
   PubMed Web of Science ®Google Scholar
• Brodbeck KJ, DesNoyer JR, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J Control Release. 1999;62(3):333–344.
   PubMed Web of Science ®Google Scholar
• Graham PD, Brodbeck KJ, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery. J Control Release. 1999;58(2):233–245.
   PubMed Web of Science ®Google Scholar
• Bouissou C, Rouse JJ, Price R, et al. The influence of surfactant on PLGA microsphere glass transition and water sorption: remodeling the surface morphology to attenuate the burst release. Pharm Res. 2006;23(6):1295–1305.
   PubMed Web of Science ®Google Scholar
• Jiang W, Schwendeman SP. Stabilization of a model formalinized protein antigen encapsulated in poly(lactide-co-glycolide)-based microspheres. J Pharm Sci. 2001;90(10):1558–1569.
   PubMed Web of Science ®Google Scholar
• Zhu G, Schwendeman SP. Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: mechanism of stabilization by basic additives. Pharm Res. 2000;17(3):351–357.
   PubMed Web of Science ®Google Scholar
• Ahn JH, Park EJ, Lee HS, et al. Reversible blocking of amino groups of octreotide for the inhibition of formation of acylated peptide impurities in poly(lactide-co-glycolide) delivery systems. AAPS PharmSciTech. 2011;12(4):1220–1226.
   PubMed Web of Science ®Google Scholar
• Murty SB, Na DH, Thanoo BC, et al. Impurity formation studies with peptide-loaded polymeric microspheres Part II. In vitro evaluation. Int J Pharm. 2005;297(1–2):62–72.
   PubMedGoogle Scholar
• Zhou J, Walker J, Ackermann R, et al. Effect of manufacturing variables and raw materials on the composition-equivalent PLGA microspheres for 1-month controlled release of leuprolide. Molecular Pharmaceutics. 2020;17(5):1502–1515.
   PubMed Web of Science ®Google Scholar
• Ruel-Gariépy E, Leroux J-C. In situ-forming hydrogels—review of temperature-sensitive systems. Eur J Pharm Biopharm. 2004;58(2):409–426.
   PubMed Web of Science ®Google Scholar
• Utterback JM, Abernathy WJ. A dynamic model of process and product innovation. Omega (Westport). 1975;3(6):639–656.
   Web of Science ®Google Scholar